MedTrace Logo

Performance of Elucirem in DSC-MRI Perfusion of Brain Gliomas

NCT06057168 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 138

Last updated 2026-01-29

Study results available
· View outcomes & findings →

Summary

This trial aimed to study the performance of Elucirem (gadopiclenol) in Dynamic Susceptibility Contrast Magnetic Resonance Imaging (DSC-MRI) perfusion of brain gliomas.

Conditions

  • Brain Tumor, Primary
  • Brain Tumor, Recurrent

Interventions

DRUG

Elucirem

Intravenous administration

DRUG

Dotarem

Intravenous administration

Sponsors & Collaborators

  • Guerbet

    lead INDUSTRY

Principal Investigators

  • Frantz Hebert · Guerbet

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-07
Primary Completion
2024-11-28
Completion
2024-11-28

Countries

  • Hungary
  • Italy
  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06057168 on ClinicalTrials.gov